![MDMA (XTC, E, ecstasy) party drug molecule. Full chemical name is 3,4-methylenedioxymethamphetamine. Skeletal formula. - NeuRA Library MDMA (XTC, E, ecstasy) party drug molecule. Full chemical name is 3,4-methylenedioxymethamphetamine. Skeletal formula. - NeuRA Library](https://library.neura.edu.au/wp-content/uploads/sites/3/2021/07/MDMA-1200x1200-cropped.jpeg)
MDMA (XTC, E, ecstasy) party drug molecule. Full chemical name is 3,4-methylenedioxymethamphetamine. Skeletal formula. - NeuRA Library
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F2.large.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F5.large.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
![3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/23/27/9107/F1.large.jpg)
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience
![3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/23/27/9107/F5.large.jpg)
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience
![3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/23/27/9107/F6.large.jpg)
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Journal of Neuroscience
![Frontiers | Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders Frontiers | Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders](https://www.frontiersin.org/files/MyHome%20Article%20Library/863552/863552_Thumb_400.jpg)
Frontiers | Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders
![Like a hug from everyone who loves you' — how MDMA could help patients with trauma - The Pharmaceutical Journal Like a hug from everyone who loves you' — how MDMA could help patients with trauma - The Pharmaceutical Journal](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/MDMA-18-1024x842.png)
Like a hug from everyone who loves you' — how MDMA could help patients with trauma - The Pharmaceutical Journal
![MDMA (XTC, E, ecstasy) party drug molecule. Full chemical name is 3,4-methylenedioxymethamphetamine. Skeletal formula. - NeuRA Library MDMA (XTC, E, ecstasy) party drug molecule. Full chemical name is 3,4-methylenedioxymethamphetamine. Skeletal formula. - NeuRA Library](https://library.neura.edu.au/wp-content/uploads/sites/3/2021/07/MDMA.jpeg)
MDMA (XTC, E, ecstasy) party drug molecule. Full chemical name is 3,4-methylenedioxymethamphetamine. Skeletal formula. - NeuRA Library
Full article: Neurotoxicity of drugs of abuse - the case of methylenedioxy amphetamines (MDMA, ecstasy ), and amphetamines
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F4.large.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F3.large.jpg)